Recent Updates
Recently added Catalysts

Anteris Technologies Global Corp.

AVRFDA catalysts, PDUFA dates & pipeline intelligence
$5.21
▼ -0.11 · -2.07%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full AVR financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $3.3052W HIGH $11.05
Volume
1.26 M
Value Traded
6.56 M
Short % Float
11.12%
Days to Cover
5.7
-11.09%Week
-17.17%1 Month
-43.68%3 Month
-42.11%6 Month
+60.33%5 Year
+60.33%All Time

Cash Data

Unlock AVR cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
507.94 M
EPS (TTM)
-1.11
P/E Ratio
-
Ent. Value
290.95 M
Total Shares
97.49 M
Float Shares
81.31 M
Insiders
16.60%
Institutions
76.90%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every AVR catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

AVR Catalyst Timeline

Dated clinical, regulatory and corporate events for Anteris Technologies Global Corp.

Unlock the full AVR catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How AVR actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all AVR historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

Anteris Technologies Global Corp. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every AVR program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
DurAVR THV severe aortic stenosis2025-11-17single digit mean gradients; large effective orifice areas (EOAs); no moderate or severe paravalvular leaks; no valve related mortality; 97% freedom from moderate or severe prosthesis-patient mismatchRead MoreAnteris Technologies Presents Data from 100 DurAVR THV Patients at PCR London Valves MINNEAPOLIS, United States and BRISBANE, Australia 17 November 2025: Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDRead More
Scroll for more · summaries link to the source press release
Unlock every AVR trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock AVR insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
L1 Capital Pty Ltd10% OwnerBuy 272,695 6,358,271 held$7.18 10/06/2026
Unlock the full AVR insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
PERCEPTIVE ADVISORS LLC 0.5 % 26.62 M 3.43 M
Unlock every fund holding AVR
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in AVR
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see AVR ownership
Insider and institutional ownership, quarter by quarter.

AVR Short Interest

Shares sold short, counted twice a month.

11.12%
Short % of Float
of tradable shares sold short
9.0M
Shares Sold Short
+14.0% vs prior count
5.7 High
Days to Cover
trading days of normal volume to buy every short share back
1.6M
Avg Daily Volume
the average used for days to cover
Unlock AVR short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

AVR Option Volume & Put-Call Ratio

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock AVR option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live AVR option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock AVR options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How AVR ranks across every disease it competes in

Competitive Position is a premium feature
See how AVR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

AVR News

AVR
Nov 16, 2026
AVRConferences/Events
▲ +5.2%on this news

Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients

Anteris Technologies announced that Dr. Rishi Puri will present one-year outcomes for the DurAVR Transcatheter Heart Valve at PCR London Valves. The study includes data from 100 patients with severe aortic stenosis. The DurAVR THV is designed to replicate normal aortic blood flow using advanced biomimetic technology.

Read more →
AVR
Nov 10, 2026
AVRGeneral
▲ +5.3%on this newsshared move

Anteris Technologies Announces Results for the Third Quarter of 2026

Anteris Technologies reported positive developments in Q3 2026, including progress in the PARADIGM Trial with expanded enrollment across multiple countries. The trial received regulatory approvals in Germany and Australia, facilitating its geographic reach. Additionally, the company has increased production capacity with a new facility and appointed a new CFO to support its commercialization efforts.

Read more →
AVR
Nov 1, 2026
AVRPhases
▼ -8.4%on this news

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

Anteris Technologies reported positive 30-day outcomes for the Medium-size DurAVR THV in patients with severe aortic stenosis. The results, presented at the TCT Conference, indicated no valve-related mortality and favorable hemodynamic profiles. The ongoing PARADIGM trial aims to further evaluate the safety and effectiveness of DurAVR THV compared to existing TAVRs.

Read more →
AVR
Oct 27, 2026
AVRConferences/Events

Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026

Anteris Technologies announced that Dr. Azeem Latib will present 30-day clinical outcomes for the medium-size DurAVR THV at TCT 2026. The presentation will focus on patients with severe aortic stenosis from the EMBARK study, which has treated over 130 patients since 2021. The conference will take place in San Diego from October 31 to November 3, 2026.

Read more →
AVR
Oct 20, 2026
AVRPhases

Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance

Anteris Technologies announced regulatory clearance from Germany's BfArM for its DurAVR® Transcatheter Heart Valve in the PARADIGM Trial. This allows patient recruitment at leading German centers, enhancing the trial's European footprint. The trial aims to evaluate the safety and effectiveness of the DurAVR® THV against existing TAVRs.

Read more →
AVR
Aug 31, 2026
AVRConferences/Events

Anteris to Present at September Healthcare Investor Conferences

Anteris Technologies Global Corp. will present at three major healthcare conferences in September 2026. CEO Wayne Paterson will discuss the company's innovative medical devices, including the DurAVR Transcatheter Heart Valve, designed to treat aortic stenosis. The conferences include the Cantor Global Healthcare Conference, Wells Fargo Healthcare Conference, and Morgan Stanley Healthcare Conference.

Read more →
AVR
Aug 11, 2026
AVRGeneral

Anteris Technologies Announces Results for the Second Quarter of 2026

Anteris Technologies reported positive Q2 2026 results, securing U.S. Medicare reimbursement for the PARADIGM Trial. The company initiated recruitment in the U.S. and expanded the trial to Denmark and the Netherlands. Additionally, new board members were appointed to strengthen governance as the DurAVR® THV moves toward commercialization.

Read more →
AVR
Jun 8, 2026
AVRFDA Updates

Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance

Anteris Technologies Global Corp. has secured full regulatory clearance from the French National Agency for Medicines and Health Products Safety for its DurAVR Transcatheter Heart Valve in the PARADIGM clinical trial. This authorization enables the company to begin patient recruitment in France, marking a key milestone in its global clinical strategy. The trial aims to evaluate the safety and efficacy of the DurAVR valve compared to available transcatheter aortic valve replacements, with an enrollment goal of approximately 1,000 patients. Anteris is committed to advancing treatment options for severe calcific aortic stenosis.

Read more →
AVR
May 13, 2026
AVRGeneral

Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors

Anteris Technologies has appointed Susan Knight and Stephen Denaro to its Board of Directors. Knight brings extensive experience from her previous roles, while Denaro returns with deep knowledge of the company. These appointments aim to strengthen governance and support the company's clinical and commercial objectives, particularly for the DurAVR® THV.

Read more →
AVR
May 13, 2026
AVRGeneral

Anteris Announces Results for the First Quarter of 2026

Anteris Technologies reported its Q1 2026 financial results, highlighting strong execution in the PARADIGM Trial with ongoing patient enrollment in Europe and the U.S. The company noted that recent CMS coverage will support recruitment efforts. However, they reported significant cash outflows due to clinical and regulatory expenses.

Read more →
AVR
May 5, 2026
AVRPhases

Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial

Anteris Technologies has announced the successful enrollment and treatment of the first U.S. patients in its global pivotal PARADIGM Trial for the DurAVR® Transcatheter Heart Valve. This trial aims to evaluate the safety and effectiveness of their innovative heart valve compared to existing transcatheter aortic valve replacements. Dr. Azeem Latib has reported promising early experiences with the new valve, highlighting the trial's importance in advancing heart care. The study is aimed at enrolling approximately 1000 patients to assess various health outcomes over the course of the trial.

Read more →
AVR
Apr 28, 2026
AVRFDA Updates

Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial

Anteris Technologies has announced that it secured U.S. Medicare reimbursement eligibility for its PARADIGM Trial, which will evaluate the DurAVR® Transcatheter Heart Valve against commercially available TAVRs. This milestone is expected to enhance U.S. site activation and operational momentum. The trial aims to enroll around 1000 patients to assess the safety and effectiveness of the DurAVR® THV.

Read more →
AVR
Feb 27, 2026
AVRGeneral

Anteris Reports 2025 Financial Results and Provides Corporate Update

Anteris Technologies reported its 2025 financial results, highlighting advancements in its DurAVR product and the initiation of the PARADIGM Trial. The company aims to strengthen its position in the structural heart market while managing significant cash outflows related to clinical and regulatory needs. CEO Wayne Paterson emphasized the importance of clinical evidence and sustainable value creation.

Read more →
AVR
Feb 27, 2026
AVRGeneral

Results for announcement to the market Name of entity: Anteris Technologies Global Corp. ("ATGC") ARBN: 677 960 235 Reporting period: For the year ended 31 December 2025 The attached Form 10-K Annual Report for the year

Anteris Technologies Global Corp. has released its Form 10-K Annual Report for the year ended December 31, 2025. The report indicates a significant decline in revenue and an increase in net losses compared to the prior year. Despite the financial challenges, Anteris is notable for its innovative DurAVR Transcatheter Heart Valve, designed to address aortic stenosis. The company continues to report on its developments and financial maneuvers in compliance with respect to ASX listing rules.

Read more →
AVR
Feb 23, 2026
AVRConferences/Events
▲ +8.5%on this news

Anteris to Present at Healthcare Investor Conferences TD Cowen and Barclays

Anteris Technologies Global Corp. will present at the TD Cowen and Barclays Healthcare Conferences. CEO Wayne Paterson will discuss the company's innovative heart devices, including the DurAVR® Transcatheter Heart Valve, designed to treat aortic stenosis. The webcasts of the presentations will be available on the company's website.

Read more →
AVR
Jan 23, 2026
AVRGeneral

Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises

Anteris Technologies has secured a $90 million strategic investment from Medtronic, contributing to a total of $320 million raised. This funding will facilitate the global pivotal PARADIGM trial for the DurAVR® Transcatheter Heart Valve (THV). Both companies aim to enhance the TAVR market through innovation and improved patient outcomes.

Read more →
AVR
Jan 23, 2026
AVRGeneral

Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock

Anteris Technologies Global Corp. has successfully closed a public offering of 40 million shares at $5.75 each, raising approximately $230 million. Additionally, the company completed a private placement of over 15 million shares to Medtronic, totaling around $320 million in gross proceeds. The funds will be used to advance their clinical strategy, particularly for the DurAVR® Transcatheter Heart Valve trial.

Read more →
AVR
Jan 21, 2026
AVRGeneral
▲ +5.4%on this newsshared move

Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic

Anteris Technologies Global Corp. has announced a proposed public offering of $200 million in common stock, with an additional $30 million option for underwriters. The company will also engage in a private placement with Medtronic for up to $90 million. Proceeds will support the DurAVR®THV global pivotal trial and expand manufacturing capabilities.

Read more →
AVR
Jan 21, 2026
AVRGeneral
▲ +5.4%on this newsshared move

Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering

Anteris Technologies Global Corp. has announced a public offering of 34,782,609 shares at $5.75 each, aiming to raise approximately $200 million. The offering is set to close on January 22, 2026, and will support the company's clinical strategy, including the DurAVR®THV global pivotal trial. Additionally, a private placement with Medtronic for up to $90 million is planned, contingent on the completion of the offering.

Read more →
AVR
Nov 17, 2025
AVRConferences/Events

Anteris Technologies Presents Data from 100 DurAVR THV Patients at PCR London Valves

Anteris Technologies Global Corp. presented promising 30-day clinical outcomes from a cohort of 100 patients with severe aortic stenosis treated with the DurAVR THV valve at the PCR London Valves conference. The data revealed single-digit mean gradients and effective orifice areas, alongside no significant complications like valve-related mortality or paravalvular leaks. The results also indicated a remarkable 97% freedom from moderate or severe prosthesis-patient mismatch, offering optimism for the valve’s performance in small aortic annuli patients. The findings are expected to bolster confidence as the company progresses towards larger trials and commercialization efforts.

Read more →

About Anteris Technologies Global Corp.

Eagan, MN 174 employees anteristech.com
Headquarters860 BLUE GENTIAN ROAD, EAGAN, MN, 55121
BIOPHARMAWATCH ELITE
Trade the next AVR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime